The use of imatinib mesylate preoperatively for a maximum of 12 months resulted in a high rate of complete microscopic resection in a group of patients with marginally resectable gastrointestinal stromal tumor (GIST), according to the results of a phase II trial.
The mTOR inhibitor everolimus (Afinitor) has been found to significantly reduce the size of angiomyolipomas, the slow-growing benign tumors commonly associated with tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis, according to the results of the phase III EXIST-2 study.
The anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody tremelimumab failed to achieve a significant improvement in survival among patients with metastatic melanoma compared with the standard of care treatments used in the comparator arm, according to the results of a phase III study.
No improvement in overall survival was seen in patients with metastatic melanoma who were assigned treatment with sorafenib in combination with carboplatin/paclitaxel for the treatment of their disease, according to the results of a double-blind, phase III study.
A new technique of robotic partial nephrectomy has the potential for better preservation of kidney function and better cancer control during partial nephrectomy by allowing surgeons more time to perform the procedure compared with traditional open surgery, according to the results of a recently published case series.
Initiating discussions about end-of-life care with patients with incurable cancers early in their disease was associated with a decrease in late-stage aggressive cancer treatments such as chemotherapy or acute care, and with an increase in the use of hospice care at the end of life.
Screening patients with renal masses with iodine-124-girentuximab had both a high specificity and sensitivity for identifying clear cell renal cell carcinoma, according to the results of a newly published open-label multicenter study.
A phase II study indicates that cabozantinib has strong antitumor activity in advanced castration-resistant prostate cancer and improves bone scan lesions.
Giving patients at the end of life regular parenteral hydration of 1 L of saline per day did not improve symptoms associated with hydration, quality of life, or survival, according to a randomized, placebo controlled study.
In mid-October, Pfizer announced that its phase III study being conducted examining axitinib (Inlyta) in treatment-naive patients with advanced renal cell carcinoma failed to meet its primary endpoint of improving progression-free survival compared with sorafenib.